BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26242220)

  • 1. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
    Rolfo C; Swaisland H; Leunen K; Rutten A; Soetekouw P; Slater S; Verheul HM; Fielding A; So K; Bannister W; Dean E
    Adv Ther; 2015 Jun; 32(6):510-22. PubMed ID: 26048134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
    Yuan P; Shentu J; Xu J; Burke W; Hsu K; Learoyd M; Zhu M; Xu B
    Cancer Chemother Pharmacol; 2019 May; 83(5):963-974. PubMed ID: 30887180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
    Plummer R; Verheul HM; De Vos FYFL; Leunen K; Molife LR; Rolfo C; Grundtvig-Sørensen P; De Grève J; Rottey S; Jerusalem G; Italiano A; Spicer J; Dirix L; Goessl C; Birkett J; Spencer S; Learoyd M; Bailey C; Dean E
    Adv Ther; 2018 Nov; 35(11):1945-1964. PubMed ID: 30324586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
    Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
    Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
    Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
    Rolfo C; Isambert N; Italiano A; Molife LR; Schellens JHM; Blay JY; Decaens T; Kristeleit R; Rosmorduc O; Demlova R; Lee MA; Ravaud A; Kopeckova K; Learoyd M; Bannister W; Locker G; de Vos-Geelen J
    Br J Clin Pharmacol; 2020 Sep; 86(9):1807-1818. PubMed ID: 32227355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
    Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
    Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    Zhou D; Li J; Learoyd M; Bui K; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H
    Clin Pharmacol Ther; 2019 Jun; 105(6):1492-1500. PubMed ID: 30585620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects.
    Damle B; Duczynski G; Jeffers BW; Crownover P; Coupe A; LaBadie RR
    Clin Ther; 2014 Feb; 36(2):236-44. PubMed ID: 24447534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib for the treatment of ovarian cancer.
    Bornstein E; Jimeno A
    Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM
    Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
    Zhou D; Li J; Bui K; Learoyd M; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H
    Clin Pharmacokinet; 2019 May; 58(5):615-625. PubMed ID: 30357650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
    Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
    Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.